Business Wire

Altium 365 Integrates with SiliconExpert, Delivering Unmatched Component Data Access to Designers Worldwide

Share

Altium, LLC (ASX: ALU), a global leader in electronics design systems, announced its integration collaboration with SiliconExpert, a leading provider of electronic component data and parts management software.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230801837887/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Altium 365 meets SiliconExpert (Graphic: Business Wire)

This integration empowers engineers, procurement professionals, and other stakeholders using Altium 365, an electronics development platform, with direct access to comprehensive, real-time component data whenever it is needed during the design and product lifecycle.

With SiliconExpert's data on over a billion electronic parts, Altium 365 users can soon access even more detailed component information than they have had before, from the simplest resistors to the most complex ICs. The data, sourced directly from manufacturers, helps ensure unparalleled accuracy and reliability in decision-making.

"We are thrilled to build the integration as part of a continuing collaboration between SiliconExpert and Altium 365," says Ananth Avva, GM and Sr. Vice President of Cloud Platform at Altium. "Supply chain of components in the electronics lifecycle management remains a key topic for many of our customers. We are continuing to enrich component data for our customers, and Silicon Expert is one source that is in high demand. We believe this integration will continue to improve the way teams across all disciplines - from designers to operations, procurement, finance, and quality and compliance - approach component selection, risk analysis, and compliance management."

The integration will offer:

  • Comprehensive Component Data: Extensive component details, from lifecycle status to environmental compliance, right within the ActiveBOM.
  • Informed Decision-making: Real-time component data to aid in making informed decisions about component selection, enhancing design quality, efficiency, and compliance.
  • Risk Management: Detailed metrics, including Year-to-End-of-Life (YTEOL) date, multi-sourcing, and inventory risks, allow for proactive risk management and strategic decision-making.
  • Accuracy and Reliability: High-quality, up-to-date data backed by SiliconExpert's strict data integrity protocols.

Altium continues to innovate in the PCB design software market, aiming to unify all aspects of the electronics product design to realization process into a single, cohesive environment. This integration with SiliconExpert reaffirms Altium's commitment to providing a comprehensive, user-friendly solution that caters not only to electronics designers but also to operations, procurement, and supply chain professionals. This approach helps ensure streamlined coordination and enhanced decision-making across all stages of product development and lifecycle for Altium’s customers.

The SiliconExpert integration will be available to Altium 365 users later this month. For more information, visit https://www.altium.com/altium-365/supply-chain/siliconexpert.

About Altium

Altium, LLC (ASX: ALU) is a global software company headquartered in San Diego, California, who is accelerating the pace of innovation through electronics. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Fabian Winkler
Product Marketing Manager, Altium LLC
fabian.winkler@altium.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 09:30:00 EET | Press release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 04:41:00 EET | Press release

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm

Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 03:15:00 EET | Press release

Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E

IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 23:10:00 EET | Press release

IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerstone of IonQ’s global strategy,” said Niccolo de Masi, Chairman and CEO of IonQ. “QuantumBasel continues to be a critical innovation node for our company as

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye